PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pt. IOPIDINE®
Apraclonidine Ophthalmic Solution, USP
0.5% w/v and 1% w/v (as apraclonidine hydrochloride)
S01EA03 Ophthalmologicals: Antiglaucoma Preparations and Miotics

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, Quebec
H9S 1A9
www.novartis.ca

Date of Preparation: February 15, 1994
Date of Revision: February 8, 2018

Submission Control No:

IOPIDINE is a registered trademark
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3
  SUMMARY PRODUCT INFORMATION ........................................................................3
  INDICATIONS AND CLINICAL USE .........................................................................3
  CONTRAINDICATIONS ...............................................................................................4
  WARNINGS AND PRECAUTIONS ..............................................................................4
  ADVERSE REACTIONS ...............................................................................................6
  DRUG INTERACTIONS ...............................................................................................10
  DRUG INTERACTIONS ...............................................................................................10
  DOSAGE AND ADMINISTRATION ............................................................................11
  OVERDOSAGE ...........................................................................................................11
  ACTION AND CLINICAL PHARMACOLOGY ............................................................12
  STORAGE AND STABILITY ......................................................................................12
  DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13

PART II: SCIENTIFIC INFORMATION ..........................................................................14
  PHARMACEUTICAL INFORMATION ..........................................................................14
  CLINICAL TRIALS .....................................................................................................14
  DETAILED PHARMACOLOGY ..................................................................................16
  TOXICOLOGY ............................................................................................................18
  REFERENCES ............................................................................................................19

PART III: PATIENT MEDICATION INFORMATION .....................................................20

PART III: PATIENT MEDICATION INFORMATION .....................................................24
IOPIDINE®
Apraclonidine Ophthalmic Solution, USP

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic (topical)</td>
<td>Ophthalmic solution/ apraclonidine 0.5% w/v and 1% w/v (as apraclonidine hydrochloride)</td>
<td>Benzalkonium chloride as preservative. For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

IOPIDINE® 1%
IOPIDINE 1% (apraclonidine ophthalmic solution) is indicated for the control or prevention of postsurgical elevations in intraocular pressure (IOP) that occur in patients after anterior segment laser ophthalmic surgery including argon laser trabecuoplasty, argon laser iridotomy and neodymium:yttrium aluminum garnet (Nd:YAG) laser posterior capsulotomy.

IOPIDINE® 0.5%
IOPIDINE 0.5% (apraclonidine ophthalmic solution) is indicated for adjunctive use in lowering intraocular pressure (IOP) and may be used as a short-term therapy in glaucoma patients on maximally tolerated medical therapy who require an additional IOP reduction.

The largest body of clinical data regarding the efficacy of apraclonidine as an adjunctive drug has been obtained in patients using timolol as the primary therapy. Apraclonidine has also been found to be effective in combination with topical betaxolol, carbachol, dipivefrin, echothiophate, epinephrine, levobunolol and pilocarpine and systemic acetazolamide and methazolamide.

The addition of IOPIDINE 0.5% to patients already using two aqueous suppressing drugs (i.e. beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide much additional benefit. Since IOPIDINE 0.5% is an aqueous suppressing drug, the addition of a third aqueous suppressant may not significantly reduce IOP.
Geriatrics (> 65 years of age):
IOPIDINE, 1% and 0.5%, is not recommended for use in the elderly as the safety and efficacy of IOPIDINE, 1% or 0.5%, have not been established in this population (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics).

Pediatrics (< 18 years of age):
IOPIDINE, 1% and 0.5%, is contraindicated for use in children as the safety and efficacy of IOPIDINE, 1% or 0.5%, have not been established in this population (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).

CONTRAINDICATIONS
IOPIDINE, 1% and 0.5%, is contraindicated in patients who are:
- Hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.
- Hypersensitive to clonidine.
- Receiving monoamine oxidase inhibitors (MAOIs).

IOPIDINE, 1% and 0.5%, is contraindicated in children (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).

WARNINGS AND PRECAUTIONS

General
NOT FOR INJECTION. Topical ophthalmic use only.

IOPIDINE, 1% and 0.5%, is a potent depressor of intraocular pressure (IOP); therefore, patients may develop exaggerated reductions in IOP and should be closely monitored.

IOPIDINE 0.5%:
In most patients, a loss of effect occurs over time. This appears to be an individual occurrence with a variable time of onset and should be closely monitored.

Use of IOPIDINE 0.5% can lead to an allergic-like reaction characterized wholly or in part by the symptoms of hyperemia, pruritus, discomfort, tearing, foreign body sensation, and edema of the lids and conjunctiva. If ocular allergic-like symptoms occur, IOPIDINE 0.5% therapy should be discontinued. The allergic-like reaction associated with apraclonidine use may be masked by seasonal allergic conjunctivitis.

Effects on ability to drive and use machinery:
IOPIDINE, 1% and 0.5%, can cause dizziness and somnolence. Patients who engage in mental activities requiring mental alertness should be warned of the potential for a decrease in mental
alertness, especially when using IOPIDINE 0.5%. Patients should be advised not to drive or operate machinery.

**Cardiovascular**
Caution should be exercised in patients with severe cardiovascular disease, including hypertension. The possibility of a vasovagal attack should be considered and caution should be exercised in patients with a history of such episodes.

Caution should also be exercised in patients with coronary insufficiency, recent myocardial infarction, cerebrovascular disease, Raynaud’s disease or thromboanginitis obliterans.

**Hepatic**
**IOPIDINE 0.5%:**
Close monitoring of patients with impaired liver function is advised as the systemic dosage form of clonidine is partly metabolized in the liver.

**Ophthalmologic**
**IOPIDINE 0.5%:**
Contact with soft contact lenses should be avoided. IOPIDINE 0.5% contains the preservative benzalkonium chloride, which may cause eye irritation and is known to discolor soft contact lenses. Patients must be instructed to remove contact lenses prior to application of IOPIDINE 0.5% and wait at least 15 minutes before re-insertion.

**Psychiatric**
**IOPIDINE 0.5%:**
Caution and monitoring of depressed patients are advised since apraclonidine has been associated with depression.

**Renal**
**IOPIDINE 0.5%:**
Close monitoring of patients with impaired renal function is advised if they are candidates for topical IOPIDINE 0.5% therapy. While systemic absorption of apraclonidine following topical administration is low (see DETAILED PHARMACOLOGY, Pharmacokinetics), structurally-related clonidine does undergo a significant increase in half-life in patients with severe renal impairment.

**Sexual Function/Reproduction**
Human clinical studies have not been performed to evaluate the effect of topical ocular administration of IOPIDINE, 1% or 0.5%, on fertility. Reproduction and fertility studies in rats showed no adverse effect on male or female fertility at doses 5 to 10 times the maximum recommended human dose.

**Special Populations**
**Pregnant Women:** IOPIDINE, 1% and 0.5%, is not recommended for use during pregnancy. The safety of IOPIDINE, 1% and 0.5%, has not been evaluated in adequate and well controlled
studies in pregnant women. Animal studies have shown that apraclonidine can have direct embryocidal effects in rabbits (see **TOXICOLOGY, Reproduction and Teratology**).

**Nursing Women:** Breastfeeding should be discontinued while using IOPIDINE, 1% and 0.5%. It is not known if topically applied IOPIDINE, 1% or 0.5%, is excreted in human milk. However, systemic clonidine can be found in mother's milk.

**Geriatrics (> 65 years of age):**
IOPIDINE, 1% and 0.5%, is not recommended for use in the elderly as the safety and efficacy of IOPIDINE, 1% or 0.5%, have not been established in this population.

**Pediatrics (< 18 years of age):** IOPIDINE, 1% and 0.5%, is contraindicated for use in children (see **CONTRAINDICATIONS**). Adverse reactions including lethargy, bradycardia and decreased oxygen saturation have been reported in neonates and infants under 1 year of age even when a single dose of IOPIDINE, 1% or 0.5%, was administered (see **ADVERSE REACTIONS, Pediatric Population**).

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**
The most commonly reported adverse events for IOPIDINE 1% in the use of laser surgery are upper lid elevation (1.3%), conjunctival blanching (0.4%) and mydriasis (0.4%).

The most commonly reported adverse events for IOPIDINE 0.5% leading to discontinuation include hyperemia, pruritus, discomfort, tearing, dry mouth, lid edema and foreign body sensation.

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*
IOPIDINE 1%:
The following adverse events were reported in association with the use of IOPIDINE 1% in laser surgery: upper lid elevation (1.3%), conjunctival blanching (0.4%) and mydriasis (0.4%).

The following adverse events were observed in investigational non-laser surgery studies in which IOPIDINE 1% was administered once or twice daily for up to 28 days

Cardiovascular disorders: bradycardia, orthostatic episode, palpitations, vasovagal attack;

Central nervous system disorders: decreased libido, dream disturbances, insomnia, irritability;

Eye disorders: allergic response, blurred or dimmed vision, burning, conjunctival blanching, conjunctival microhemorrhage, discomfort, dryness, foreign body sensation, hypotony, itching, mydriasis, upper lid elevation;

Gastrointestinal disorders: abdominal pain, diarrhea, discomfort, emesis stomach;

Other disorders: body heat sensation, chest heaviness or burning, clammy or sweaty palms, dry mouth, extremity pain or numbness, fatigue, headache, head cold sensation, increased pharyngeal secretion, nasal burning or dryness, paresthesia, pruritus not associated with rash, shortness of breath, taste abnormalities.
Table 1 - Treatment-related adverse reactions (incidence rate ≥ 2.0%) in placebo-controlled clinical studies of IOPIDINE 0.5%

<table>
<thead>
<tr>
<th>Coded Adverse Event</th>
<th>SINGLE THERAPY N=183</th>
<th>ADJUNCTIVE + MAXIMAL THERAPY N=152</th>
<th>PLACEBO N=160</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td><strong>Ocular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>24</td>
<td>13.1</td>
<td>14</td>
</tr>
<tr>
<td>Discomfort</td>
<td>19</td>
<td>10.4</td>
<td>5</td>
</tr>
<tr>
<td>Hyperemia</td>
<td>15</td>
<td>8.2</td>
<td>25</td>
</tr>
<tr>
<td>Tearing</td>
<td>11</td>
<td>6.0</td>
<td>5</td>
</tr>
<tr>
<td>Dry Eye</td>
<td>6</td>
<td>3.3</td>
<td>1</td>
</tr>
<tr>
<td>Foreign Body Sensation</td>
<td>5</td>
<td>2.7</td>
<td>4</td>
</tr>
<tr>
<td>Lid Edema</td>
<td>5</td>
<td>2.7</td>
<td>3</td>
</tr>
<tr>
<td>Blaniching</td>
<td>5</td>
<td>2.7</td>
<td>0</td>
</tr>
<tr>
<td>Blurred Vision</td>
<td>2</td>
<td>1.1</td>
<td>4</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>2</td>
<td>1.1</td>
<td>3</td>
</tr>
<tr>
<td><strong>Nonocular</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body as a Whole</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>8</td>
<td>4.4</td>
<td>1</td>
</tr>
<tr>
<td>Asthenia</td>
<td>7</td>
<td>3.8</td>
<td>0</td>
</tr>
<tr>
<td>Central Nervous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>System Somnolence</td>
<td>4</td>
<td>2.2</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>0.5</td>
<td>3</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>39</td>
<td>21.3</td>
<td>4</td>
</tr>
<tr>
<td>Constipation</td>
<td>5</td>
<td>2.7</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry Nose</td>
<td>11</td>
<td>6.0</td>
<td>0</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>4</td>
<td>2.2</td>
<td>0</td>
</tr>
<tr>
<td>Special Senses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste Perversion</td>
<td>10</td>
<td>5.5</td>
<td>2</td>
</tr>
</tbody>
</table>

N = sample size

Use of IOPIDINE 0.5% can lead to an allergic-like reaction characterized wholly or in part by the symptoms of hyperemia, pruritus, discomfort, tearing, foreign body sensation, and edema of the lids and conjunctiva.

The overall discontinuation rate in clinical studies with IOPIDINE 0.5% was 16%. The most commonly reported events leading to discontinuation included (in decreasing order of frequency) hyperemia, pruritus, discomfort, tearing, dry mouth, lid edema, and foreign body sensation.
The following adverse reactions (incidence) were reported in clinical studies of IOPIDINE 0.5% as being related to therapy:

**Ocular:** Hyperemia (11.9%), pruritus (11.3%), discomfort (7.2%), tearing (4.8%), foreign body sensation (2.7%), lid edema (2.4%), dry eye (2.1%), blurred vision (1.8%), blanching (1.5%), conjunctivitis (1.5%), lid margin crusting (1.2%).

**Body as a whole:** Headache (2.7%), asthenia (2.1%).

**Central nervous system:** Somnolence (1.2%), dizziness (1.2%).

**Digestive system:** Dry mouth (12.8%), constipation (1.5%).

**Respiratory system:** Dry nose (3.3%), rhinitis (1.2%).

**Special senses:** Taste perversion (3.6%).

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

**Ocular:** Conjunctival edema (0.9%), discharge (0.9%), abnormal vision (0.9%), pain (0.6%), lid disorder (0.6%), edema (0.6%), lid erythema (0.6%), irritation (0.3%), keratitis (0.3%), blepharitis (0.3%), blepharoconjunctivitis (0.3%), photophobia (0.3%), conjunctival follicles (0.3%), scleritis (0.3%), keratopathy (0.3%), lid scales (0.3%), corneal infiltrate (0.3%), corneal staining (0.3%).

**Body as a whole:** Chest pain (0.6%), abnormal coordination (0.3%), malaise (0.3%).

**Cardiovascular:** Peripheral edema (0.3%), arrhythmia. Although no reports of bradycardia related to 0.5% Apraclonidine Hydrochloride Ophthalmic Solution were available from clinical studies, the possibility of its occurrence based on apraclonidine's alpha 2 agonist effect should be considered.

**Central nervous system:** Depression (0.6%), nervousness (0.6%), insomnia (0.3%), paresthesia (0.3%).

**Digestive system:** Nausea (0.6%).

**Musculoskeletal system:** Myalgia (0.3%).

**Respiratory system:** Dyspnea (0.3%), pharyngitis (0.3%).

**Skin:** Contact dermatitis (0.3%), dermatitis (0.3%).

**Special senses:** Parosmia (0.3%).
Post-Market Adverse Drug Reactions
IOPIDINE 1%:
The following adverse reactions were seen either in subsequent clinical trials or via spontaneous post-market reporting:

Eye disorders: conjunctival vascular disorder, eyelid retraction, ocular hyperemia, punctate keratitis;
Gastrointestinal disorders: nausea;
Nervous system disorders: dizziness postural, presyncope, syncope;
Vascular disorders: hypertension, hypotension.
Immune system disorders: hypersensitivity

IOPIDINE 0.5%:
The following adverse reactions were seen either in subsequent clinical trials or via spontaneous post-market reporting:

Eye disorders: blepharospasm, conjunctival vascular disorders, eyelid ptosis, mydriasis, visual acuity reduced;
General disorders and administration site conditions: fatigue, irritability;
Respiratory, thoracic and mediastinal disorders: rhinorrhea, throat irritation;
Vascular disorders: vasodilation.
Immune system disorders: hypersensitivity

Pediatric Population
IOPIDINE, 1% and 0.5%, is contraindicated for use in children. Adverse reactions including lethargy, bradycardia and decreased oxygen saturation have been reported in neonates and infants under 1 year of age even when a single dose of apraclonidine was administered.

DRUG INTERACTIONS

Overview
IOPIDINE, 1% and 0.5%, is contraindicated in patients receiving monoamine oxidase inhibitors (MAOIs).

There is the potential for interactions with CNS depressants, tricyclic antidepressants, beta-blockets, antihypertensives and cardiac glycosides.

Drug-Drug Interactions
IOPIDINE, 1% and 0.5%, is contraindicated in patients receiving monoamine oxidase inhibitors (MAOIs). Alpha-antagonists, including apraclonidine, could potentiate the centrally mediated effects of MAOIs, in particular the side effects of orthostatic hypotension. Concomitant use of alpha-antagonists and MAOIs could produce a profound synergistic hypotensive effect and cause cardiovascular collapse in sensitive patients.

The possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be borne in mind.
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect. No data on the level of circulating catecholamines after apraclonidine withdrawal are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised. Patients using cardiovascular drugs concurrently with apraclonidine should have pulse and blood pressures frequently monitored. Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents.

**IOPIDINE 0.5%:**
No specific drug interactions with topical glaucoma drugs (betaxolol, carbachol, dipivefrin, echothiopate, epinephrine, levobunolol, pilocarpine, timolol) or systemic medications (acetazolamide, methazolamide) were identified in clinical studies with IOPIDINE 0.5%.

**DOSAGE AND ADMINISTRATION**

**Recommended Dose and Dose Adjustment**

**IOPIDINE 1%:**
One drop of IOPIDINE 1% should be instilled in the scheduled operative eye one hour before initiating anterior segment laser surgery and a second drop should be instilled in the same eye immediately upon completion of the laser surgical procedure. Use a separate container for each single drop dose and discard each container after use.

**IOPIDINE 0.5%:**
One to two drops of IOPIDINE 0.5% should be instilled in the affected eye(s) two or three times daily. Since IOPIDINE 0.5% will be used with other ocular glaucoma therapies, an approximate 5 minute interval between instillation of each medication should be practised to prevent washout of the previous dose.

**Missed Dose**

**IOPIDINE 0.5%:**
If a dose is missed, a single drop should be applied as soon as possible before reverting to the regular dose. Do not use a double dose to make up for a missed dose.

**OVERDOSAGE**

Overdose is unlikely with topical ocular instillation, as the volume of exposure is limited by the capacity of the cul-de-sac. The small volume packaging and unique design of the DROP-TAINER® limit the potential for accidental overdosage by ingestion.
Signs of toxicity of apraclonidine in animals include lethargy, decreased activity, loss of appetite, hypothermia, decreased GI motility and constipation. Following oral administration of apraclonidine to monkeys, plasma levels 100 times greater than those seen in human plasma level studies were associated with moderate signs of toxicity, including lethargy, hypoactivity, and loss of appetite; no significant target organ toxicities were found. Acute oral toxicity studies in rats and mice resulted in LD₅₀ values of 64 and 5 mg/kg, respectively. While higher doses usually caused deaths within 24 hours, lower doses often resulted in delayed deaths.

While no instances of human ingestion of IOPIDINE, 1% and 0.5%, are known, overdose with the oral form of clonidine has been reported to cause hypotension, transient hypertension, asthenia, vomiting, irritability, diminished or absent reflexes, lethargy, somnolence, sedation or coma, pallor, hypothermia, bradycardia, conduction defects, arrhythmias, dryness of the mouth, miosis, apnea, respiratory depression, hypoventilation, and seizure, particularly in children.

Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. Gastric lavage, IV fluids, atropine, dopamine, tolazoline, furosemide and diazoxide have been reported to be useful in treating the systemic symptoms associated with oral clonidine overdose. Hemodialysis is of limited value, since a maximum of 5% of circulating drug is removed.

An ocular overdose can be flushed from the eye(s) with lukewarm water.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

**ACTION AND CLINICAL PHARMACOLOGY**

Apraclonidine is a relatively selective alpha adrenergic agonist and does not have significant membrane stabilizing (local anaesthetic) activity. When instilled into the eye, apraclonidine has the action of reducing intraocular pressure (IOP). Aqueous fluorophotometry studies in humans demonstrate that apraclonidine's predominant mechanism of action is reduction of aqueous flow via stimulation of the alpha-adrenergic system.

Apraclonidine is a partial agonist for alpha 1 and alpha 2 adrenergic receptors. The affinity of apraclonidine for alpha 2 receptors, as measured by competitive radioligand binding studies, is much higher than its affinity toward alpha 1 receptors.

The onset of action of apraclonidine can usually be noted within one hour following administration. The maximum IOP reduction usually occurs three to five hours after application of a single dose.

**STORAGE AND STABILITY**

DOSAGE FORMS, COMPOSITION AND PACKAGING

IOPIDINE 1%:
IOPIDINE 1% is a sterile isotonic aqueous solution containing:
Medicinal ingredient: apraclonidine hydrochloride 1.15% equivalent to 1% apraclonidine base
Preservative: benzalkonium chloride 0.01%
Non-medicinal ingredients: sodium chloride, sodium acetate, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water.

IOPIDINE 1% is supplied as follows: 0.1 mL in plastic ophthalmic dispensers, packaged two per pouch. These dispensers are enclosed in a foil overwrap as an added barrier to evaporation.

IOPIDINE 0.5%:
IOPIDINE 0.5% is a sterile isotonic aqueous solution containing:
Medicinal ingredient: apraclonidine hydrochloride 0.575% equivalent to 0.5% apraclonidine base
Preservative: benzalkonium chloride 0.01%
Non-medicinal ingredients: sodium chloride, sodium acetate, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water.

IOPIDINE 0.5% is supplied in a 5 mL plastic DROP-TAINER® dispenser.

Tamper evidence is provided by a closure with an extended skirt that locks to the bottle finish on application and breaks away from the closure on opening. After cap is removed: if tamper evident snap collar is loose, remove before using product.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Apraclonidine hydrochloride

Chemical name: 2-[(4-Amino-2,6-dichlorophenyl)imino]imidazolidine monohydrochloride

Molecular formula and molecular mass: $C_9H_{10}Cl_2N_4\cdot HCl; 281.6$

Structural formula:

Physicochemical properties: Apraclonidine hydrochloride is a white to off-white powder and is highly soluble in water.

CLINICAL TRIALS

Laser Surgery Therapy

Optic nerve head damage and visual field loss may result from an acute elevation in intraocular pressure (IOP) that can occur after surgical procedures. Elevated IOP, whether acute or chronic in duration, is a major risk factor in the pathogenesis of visual field loss. The higher the peak or spike of IOP, the greater the likelihood of visual field loss and optic nerve damage especially in patients with previously compromised optic nerves.

Placebo-controlled clinical studies in patients requiring argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG laser posterior capsulotomy showed that IOPIDINE® 1% apraclonidine ophthalmic solution) controlled or prevented the postsurgical IOP rise typically observed in patients after undergoing those procedures. After surgery, the mean IOP was 1.9 to 4.0 mmHg below the corresponding pre-surgical baseline pressure before IOPIDINE 1% treatment.

With placebo treatment, postsurgical pressures were 2.5 to 8.4 mmHg higher than their corresponding pre-surgical baselines. Overall, only 2% of patients treated with IOPIDINE 1% had severe IOP elevations (spikes $\geq 10$ mm Hg) during the first three hours after laser surgery, whereas 23% of placebo-treated patients responded with severe pressure spikes (Table 2). Of the patients that experienced a pressure spike after surgery, the peak IOP was above the 30 mmHg in
most patients (Table 3) and was above 50 mmHg in seven placebo-treated patients and one IOPIDINE 1% -treated patient.

Table 2: Incidence of Postsurgical Intraocular Pressure Spikes ≥ 10 mmHg Following Laser Surgery Therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>Laser Procedure</th>
<th>Treatment</th>
<th>Apraclonidine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>1</td>
<td>Overall</td>
<td>0/76</td>
<td>0</td>
<td>22/79</td>
</tr>
<tr>
<td>2</td>
<td>Overall</td>
<td>3/84</td>
<td>4</td>
<td>15/84</td>
</tr>
<tr>
<td>1</td>
<td>Trabeculoplasty</td>
<td>0/50</td>
<td>0</td>
<td>12/51</td>
</tr>
<tr>
<td>2</td>
<td>Trabeculoplasty</td>
<td>2/41</td>
<td>5</td>
<td>8/42</td>
</tr>
<tr>
<td>1</td>
<td>Iridotomy</td>
<td>0/13</td>
<td>0</td>
<td>8/19</td>
</tr>
<tr>
<td>2</td>
<td>Iridotomy</td>
<td>0/18</td>
<td>0</td>
<td>4/19</td>
</tr>
<tr>
<td>1</td>
<td>Posterior Capsulotomy</td>
<td>0/8</td>
<td>0</td>
<td>2/9</td>
</tr>
<tr>
<td>2</td>
<td>Posterior Capsulotomy</td>
<td>1/25</td>
<td>4</td>
<td>3/23</td>
</tr>
</tbody>
</table>

N = Number Spikes/Number Eyes

Table 3: Magnitude of Postsurgical Intraocular Pressure in Patients with Severe Pressure Spikes ≥ 10 mmHg Following Laser Surgery Therapy

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total Spikes</th>
<th>Maximum Postsurgical Intraocular Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>20-29 mmHg</td>
</tr>
<tr>
<td>Apraclonidine</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Placebo</td>
<td>37</td>
<td>3</td>
</tr>
</tbody>
</table>

**Glaucoma Therapy:**

Dose-response and comparative studies (0.125% - 1.0% apraclonidine) demonstrate that 0.5% apraclonidine is at the top of the dose/response IOP reduction curve. Based upon the dose response and efficacy studies, and the incidence of ocular allergic and systemic side effects (see **WARNINGS AND PRECAUTIONS**), IOPIDINE 0.5% is recommended for short term use in glaucoma patients on maximally tolerated medical therapy who require an additional IOP reduction.

The utility of IOPIDINE 0.5% is most apparent for those glaucoma patients on maximally tolerated medical therapy. In such patients, IOPIDINE 0.5% provided further IOP reductions of 2.1 to 3.2 mmHg for three months, even when patients were using a beta-blocker, epinephrine, pilocarpine, and oral carbonic anhydrase inhibitors, and had undergone laser trabeculoplasty. Among those patients on maximally tolerated medical therapy whose IOP remained uncontrolled at 22 mmHg or greater, IOPIDINE 0.5% was particularly effective, providing an additional IOP reduction of 3.7 to 5.0 mmHg. Filtration surgery was performed in about 15% of patients due to treatment failure; the average therapy time before surgery was 4.3 months. An additional 19.8% of patients were discontinued due to adverse events, primarily allergic-like reactions. Thus, in approximately 67% of the patients, IOPIDINE 0.5% provided substantial control of glaucoma.
Adjunctive therapy studies in glaucoma patients demonstrated that IOPIDINE 0.5% dosed BID for 90 days in patients receiving 0.5% timolol, effectively lowered IOP by an additional 2.5 to 5.0 mmHg. The additional IOP reduction with apraclonidine is more pronounced shortly (3 hrs) after instillation. IOPIDINE 0.5% as a single therapy dosed TID for 90 days effectively lowered IOP by 3.9 to 7.9 mmHg in glaucoma patients. Although afternoon IOP reduction is comparable between a beta-blocker and IOPIDINE 0.5%, a beta-blocker is more effective in reducing morning IOP than IOPIDINE 0.5%.

The IOP lowering efficacy of IOPIDINE 0.5% is diminished over time in some patients. This loss of control, or tachyphylaxis, appears to be an individual occurrence with an unpredictable onset.

Approximately 20% of patients treated with IOPIDINE 0.5% experienced apparent ocular allergic responses (mean onset time 38.6 days, with a range of 1 to 158 days), which resolved upon discontinuation of drug therapy.

The overall discontinuation rates in clinical studies with IOPIDINE 0.5% ranged from 14.8% in single therapy studies to 21.5% in adjunctive therapy studies.

The unpredictable loss of IOP control in some patients and incidence of ocular allergic responses and systemic side effects may limit the length of use of IOPIDINE 0.5% as a single, or adjunctive, medication in long term use. However, patients on maximally tolerated medical therapy still benefit from the additional IOP reduction provided by the short term use of IOPIDINE 0.5%.

DETAILED PHARMACOLOGY

Pharmacodynamics

Human Studies:
Mechanism of Action: Apraclonidine is a relatively selective alpha-2 adrenergic agonist and does not have significant membrane stabilizing (local anaesthetic) activity. When instilled in the eye, apraclonidine has the action of reducing elevated, as well as normal, intraocular pressure (IOP), whether or not accompanied by glaucoma.

Aqueous fluorophotometry studies in humans demonstrate that apraclonidine's predominant mechanism of action is reduction of aqueous flow via stimulation of the alpha-adrenergic system. Unlike beta-blockers and epinephrine, apraclonidine reduces aqueous flow during the day and also at night during sleep. Apraclonidine's mechanism of action may account for the additional IOP reductions observed after instillation of Apraclonidine Ophthalmic Solution in patients receiving a beta-blocker or receiving maximally tolerated medical therapy.

Cardiovascular: In a safety study involving 21 healthy volunteers administered 1 drop of 1% apraclonidine hydrochloride ophthalmic solution twice daily for 28 consecutive days, no clinically significant effects attributable to the drug could be found when blood pressure and heart rate were measured.
Central Nervous System Effects: A statistically significant decreased IOP was observed in the contralateral eye of normal volunteers treated unilaterally with 1% apraclonidine hydrochloride ophthalmic solution. During the seven hour period following treatment, there was a mean maximum decrease of $6.5 \pm 4.3$ mmHg in the treated eye (a $37.3\% \pm 20.4\%$ decrease from pre-treatment baseline) and a mean maximum decrease of $2.7 \pm 3.4$ mmHg in the contralateral eye (a $14.9\% \pm 19\%$ decrease from pre-treatment baseline).

Ocular Effects: IOPIDINE 0.5% does not produce miosis or myopia commonly associated with cholinergic agents. The blurred vision and night blindness often observed with standard miotic therapy are not associated with IOPIDINE 0.5%. Thus patients with central lenticular opacities avoid the visual impairment caused by a constricted pupil.

Animal Studies:
Blood Flow Effects: Apraclonidine Ophthalmic Solution, because of its alpha adrenergic activity, is a vasoconstrictor. Single dose ocular blood flow studies in monkeys, using the microsphere technique, demonstrated a reduced blood flow for the anterior segment; however, no reduction in blood flow was observed in the posterior segment of the eye after a topical dose of 0.5% Apraclonidine Ophthalmic Solution. Chronic treatment of primates with 1.5% Apraclonidine Ophthalmic Solution three times a day for one year did not result in morphologic effects which would be indicative of vasoconstriction of the anterior or posterior segments of the eye. Ocular blood flow studies have not been conducted in humans.

Pharmacokinetics:
Human Studies:
The onset of action of apraclonidine can usually be noted within one hour, and the maximum IOP reduction occurs three to five hours after application. Significant IOP reduction can be maintained with 0.5% Apraclonidine Ophthalmic Solution; the duration of action in some patients is less than 12 hours.

Topically administered apraclonidine is absorbed systematically and is present at low concentrations in the plasma. Studies of 0.5% Apraclonidine Ophthalmic Solution dosed one drop three times a day in both eyes for 10 days in normal volunteers yielded mean peak and trough apraclonidine plasma concentrations of 0.9 ng/mL and 0.5 ng/mL, respectively. The half-life of apraclonidine was calculated to be 8 hours. Protein binding has been measured in human plasma by ultrafiltration and equilibrium dialysis (3). Both methods indicated the extent of binding to be low (22-29%). These data are consistent with the low frequency of systemic side effects observed with apraclonidine in controlled clinical studies.

Animal Studies:
Studies in rabbits with radiolabeled apraclonidine have demonstrated absorption into the eye after topical ocular administration. In the iris-ciliary body, aqueous humor and lens, maximal concentrations were reached at approximately 2 hours after dosing (1.4, 0.5, and 0.2 ug equivalents/gm, respectively). The half-life of apraclonidine in the aqueous humor was approximately 2 hours. Concentrations of 4.7 ug equivalents/gm were measured in the cornea at 20 minutes post-dose.
Following IV administration, the plasma half-life of parent apraclonidine was 9 hours in the Cynomolgus monkey and 3 hours in the rat. In both species the half-life of radioactivity from $^3$H-apraclonidine was longer than that of the parent drug. Approximately 10 metabolites were identified in rat urine and plasma. In both rats and Cynomolgus monkeys, urinary excretion was the primary route of elimination (65-75% of dose) with the balance eliminated in the feces.

**TOXICOLOGY**

**Acute Toxicity**
The oral LD$_{50}$ of the drug ranged from 3 to 8 mg/kg in mice and 38 to 107 mg/kg in rats. The intravenous LD$_{50}$ of the drug ranged from 6 to 9 mg/kg in mice and 9 to 21 mg/kg in rats. LD$_{50}$ values in these ranges are indicative of a drug with a high degree of toxicity. Mortalities occurred one (1) to nine (9) days after administration, with systemic signs of toxicity including lethargy, impaired motor co-ordination and partial loss of consciousness. Bloody tears and/or urine and hypothermia were observed at extremely high doses ($\geq$ 80 mg/kg).

**Long Term Toxicity**
Topical ocular administration of two drops of 0.5, 1.0 and 1.5% Apraclonidine Hydrochloride Ophthalmic Solution to New Zealand albino rabbits three times daily for one month resulted in sporadic and transient instances of minimal corneal edema in the 1.5% group only. No histopathological changes were noted in the affected eyes.

Topical ocular administration of 1.5% Apraclonidine Hydrochloride Ophthalmic Solution three times daily for one year to Cynomolgus monkeys elicited minimal conjunctival congestion and single instances of transient and sporadic fluorescein staining. No corneal cloudiness, iritis or lenticular changes were observed.

**Reproduction and Teratology**
Reproduction and fertility studies in rats showed no adverse effect on male or female fertility at doses 5 to 10 times the maximum recommended human dose.

Teratogenicity studies with apraclonidine HCl in rabbits and rats at doses up to 3.0 mg/kg/day in rabbits (60 times the maximum recommended human dose) and 0.3 mg/kg/day in rats (6 times the maximum recommended human dose) showed no evidence of fetal malformations. Embryotoxicity, however, was evident at the high dose level in the rabbit study. Dose-related maternal toxicity was evident in both the rat and rabbit studies.

**Mutagenicity**
No evidence of apraclonidine-induced mutagenicity was observed in *in vitro* microbial (Ames test), mammalian (mouse lymphoma), chromosome aberration, sister chromatid exchange, or malignant transformation test assays or in an *in vivo* micronucleus assay.
**Carcinogenicity**
There was no significant increase in tumour incidence or type following two years of oral administration of apraclonidine HCl to rats at dose levels 20 times the maximum recommended human dose or in mice at dose levels 12 times the maximum recommended human dose.

**Other Studies**
Two sensitization assays were performed in animals: the Buehler occlusive patch test in guinea pigs and the guinea pig maximization test (GPMT). While the Buehler test suggested little or no potential for sensitization, the GPMT revealed a moderate sensitization potential, indicating that there may be patients who develop a contact sensitization response with repeated use of this drug.

**REFERENCES**


READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

Pr IOPIDINE® 1%
Apraclonidine Ophthalmic Solution, USP

Read this carefully before you start taking IOPIDINE® 1% and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about IOPIDINE 1%.

What is IOPIDINE 1% used for?
- Control or prevention of increases in eye pressure (intraocular pressure) following certain types of laser eye surgery.

How does IOPIDINE 1% work?
IOPIDINE 1% contains apraclonidine, an alpha adrenergic agonist. It works by reducing the production of liquid in the eye as well as by increasing the rate liquid flows out of the eye.

What are the ingredients in IOPIDINE 1%?
Medicinal ingredient: Apraclonidine 1% w/v (as apraclonidine hydrochloride)
Non-medicinal ingredients: Benzalkonium chloride (preservative), sodium acetate, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water

IOPIDINE 1% comes in the following dosage forms:
Eye drop solution in 0.1 mL plastic dispensers packaged 2 per pouch

Do not use IOPIDINE 1% if you are:
- Allergic (hypersensitive) to apraclonidine or any of the other ingredients in IOPIDINE 1% (see What are the ingredients in IOPIDINE 1%?).
- Allergic to clonidine.
- Taking monoamine oxidase inhibitors (MAOIs).

IOPIDINE 1% must not be used in children under 18 years of age.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take IOPIDINE 1%. Talk about any health conditions or problems you may have, including if you:
- Have or have had any heart conditions or blood circulation problems, such as:
  o high blood pressure.
  o a sudden drop in heart rate and blood pressure (vasovagal attack).
  o not enough blood flow in the arteries (coronary insufficiency).
  o heart attack or stroke.
  o lower blood flow to the fingers and/or toes (Raynaud’s disease).
  o blocked blood vessels in the hands and/or feet (thromboanginitis obliterans).
• Are pregnant or plan to become pregnant. You should not use IOPIDINE 1% while you are pregnant.
• Are breastfeeding or plan to breast-feed. You should not breast-feed while using IOPIDINE 1%.

Other warnings you should know about:
You may become dizzy or sleepy after taking IOPIDINE 1%. Do not drive or operate machines until these symptoms pass.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with IOPIDINE 1%:
• Monoamine oxidase inhibitors (MAOIs).
• Alcohol.
• Antidepressants, including barbiturates and tricyclic antidepressants.
• Opiates (class of painkillers).
• Sedatives.
• Anesthetics.
• Beta-blockers (medicines used to treat some heart problems).
• Anti-hypertensives (medications used to treat high blood pressure).
• Heart medications, including those used to treat heart failure and irregular heartbeats.

How to take IOPIDINE 1%:
Your doctor or nurse will apply IOPIDINE 1% for you. A separate container will be used for each single drop. Each container will be discarded after use.

Usual adult dose:
1 drop in the eye scheduled for surgery 1 hour before surgery followed by 1 drop in the same eye after surgery.

Overdose:
An overdose is unlikely as your doctor or nurse will apply IOPIDINE 1% for you.

If you think you have been given too much IOPIDINE 1%, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

What are possible side effects from using IOPIDINE 1%?
These are not all the possible side effects you may feel when taking IOPIDINE 1%. If you experience any side effects not listed here, contact your healthcare professional. Please also see Warnings and Precautions.

Side effects seen with IOPIDINE 1% used in laser surgery include:
- Raised upper eyelid or widely opened eyes.
- White appearance in the eyes.
- Dilated pupils.
- Red eye.
- Damage to the cornea.
- Nausea.
- Dizziness when standing.
- Feeling faint or fainting.
- Low or high blood pressure.
- Allergy (hypersensitivity)

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

**Reporting Side Effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:
- Online at MedEffect;
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 1908C
    Ottawa, ON
    K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**Storage:**

Your doctor or nurse will store IOPIDINE between 2°C and 30°C. Protect from light.

**If you want more information about IOPIDINE 1%:**
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website; the manufacturer’s website www.novartis.ca, or by calling 1-800-363-8883.

This leaflet was prepared by Novartis Pharmaceuticals Canada Inc.

Last Revised: November 28, 2017
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

Pr IOPIDINE® 0.5%
Apraclonidine Ophthalmic Solution, USP

Read this carefully before you start taking IOPIDINE® 0.5% and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about IOPIDINE 0.5%.

What is IOPIDINE 0.5% used for?
IOPIDINE 0.5% is used with other medication to lower high pressure in the eyes. If left untreated, this high pressure can eventually damage the eyes.

How does IOPIDINE 0.5% work?
IOPIDINE 0.5% contains apraclonidine, an alpha adrenergic agonist. It works by reducing the production of liquid in the eye as well as by increasing the rate liquid flows out of the eye.

What are the ingredients in IOPIDINE 0.5%?
Medicinal ingredient: apraclonidine hydrochloride
Non-medicinal ingredients: benzalkonium chloride (preservative), sodium acetate, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water

IOPIDINE 0.5% comes in the following dosage forms:
Eye drop solution, 0.5% w/v, in a 5 mL dispenser bottle

Do not use IOPIDINE 0.5% if you are:
- Allergic (hypersensitive) to apraclonidine or any of the other ingredients in IOPIDINE 0.5% (see What are the ingredients in IOPIDINE 0.5%?).
- Allergic to clonidine.
- Taking monoamine oxidase inhibitors (MAOIs).

IOPIDINE 0.5% must not be used in children under 18 years of age.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take IOPIDINE 0.5%. Talk about any health conditions or problems you may have, including if you:
- Have or have had any heart conditions or blood circulation problems, such as
  - high blood pressure.
  - a sudden drop in heart rate and blood pressure (vasovagal attack).
  - not enough blood flow in the arteries (coronary insufficiency).
  - heart attack or stroke.
  - lower blood flow to the fingers and/or toes (Raynaud’s disease).
  - blocked blood vessels in the hands and/or feet (thromboanginitis obliterans).
- Have liver or kidney problems.
- Are or have been depressed.
- Are pregnant or plan to become pregnant. You should not use IOPIDINE 0.5% while you are pregnant.
- Are breastfeeding or plan to breast-feed. You should not breast-feed while using IOPIDINE 0.5%.

**Other warnings you should know about:**
Over time, IOPIDINE 0.5% may not work as well. Your doctor should monitor you closely.

If you feel any eye allergy symptoms, such as redness, itching, increased tearing, or swelling, stop using IOPIDINE 0.5% and talk to your doctor.

You may become dizzy, sleepy or less alert after taking IOPIDINE 0.5%. Do not drive or operate machines until these symptoms pass.

**Contact lens wearers**
IOPIDINE 0.5% contains the preservative benzalkonium chloride, which can stain contact lenses and cause eye irritation. Remove your contact lenses before applying IOPIDINE 0.5%. Wait at least 15 minutes before you put your contacts back in.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with IOPIDINE 0.5%:**
- Monoamine oxidase inhibitors (MAOIs).
- Alcohol.
- Antidepressants, including barbiturates and tricyclic antidepressants.
- Opiates (class of painkillers).
- Sedatives.
- Anesthetics.
- Beta-blockers (medicines used to treat some heart problems).
- Anti-hypertensives (medications used to treat high blood pressure).
- Heart medications, including those used to treat heart failure and irregular heartbeats.

**How to take IOPIDINE 0.5%:**
Always use IOPIDINE 0.5% exactly as your doctor has told you.

- Get the IOPIDINE 0.5% bottle and a mirror (if needed).
- Wash your hands.
- Twist off the cap. If the security snap collar is loose after removing the cap, remove the snap collar before using IOPIDINE 0.5%.
- Hold the bottle, pointing down, between your thumb and fingers.
- Tilt your head back. Pull down your eyelid with a clean finger, until there is a ‘pocket’ between the eyelid and your eye. The drop will go in here (picture 1).
- Bring the bottle tip close to the eye. Use the mirror if it helps.
- Don’t touch your eye or eyelid, surrounding areas or other surfaces with dropper. It could contaminate the drops.
- Gently press on the base of the bottle to release one drop of IOPIDINE 0.5% at a time (picture 2). Do not squeeze the bottle: it is designed so that a gentle press on the bottom of the bottle is all that it needs.
- If you miss the eye, wipe up and try again.
- If you take drops in both eyes, repeat the steps for your other eye.
- Close the bottle cap firmly immediately after use.

Wait at least 5 minutes between applying each eye drop solution you are taking, including IOPIDINE 0.5%.

**Usual adult dose:**
Apply 1-2 drops in the eye(s) 2 or 3 times a day. Wait at least 5 minutes between applying each eye drop solution you are taking, including IOPIDINE 0.5%.

**Overdose:**
If you apply more IOPIDINE 0.5% than you should, rinse your eyes with lukewarm water. Do not apply any more drops until it is time for your next regular dose.

| If you think you have accidentally ingest IOPIDINE 0.5%, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms. |

**Missed Dose:**
If you forget to apply IOPIDINE 0.5%, apply a single drop as soon as you remember. If it is close to your next regular dose, skip the missed dose. Do not use a double dose to make up for the missed dose.

**What are possible side effects from using IOPIDINE 0.5%?**

These are not all the possible side effects you may feel when taking IOPIDINE 0.5%. If you experience any side effects not listed here, contact your healthcare professional. Please also see Warnings and Precautions.

**Related to the eyes:**
- Redness.
- Itching.
- Discomfort.
• Increased tearing.
• Swelling.
• A feeling that something is in eye.
• Dry eye.
• Blurred, abnormal or reduced vision.
• Eyelid margin crusting or scales.
• Discharge.
• Damage to or staining of the cornea.
• Eyelid redness, itching, or swelling.
• Pain.
• Irritation.
• Sensitivity to light.
• Eyelid spasms or drooping.
• Dilation of the pupils.

**Related to rest of body:**

• Dry mouth.
• Headache.
• Feeling unwell or tired.
• Chest pain.
• Coordination problems.
• Swelling of the hands or feet.
• Abnormal heartbeat.
• Sleepiness.
• Drowsiness.
• Depression.
• Nervousness.
• Difficulty sleeping.
• Tingling of the hands or feet.
• Constipation.
• Nausea.
• Muscle pain.
• Dry nose.
• Itchy nose or throat.
• Problems breathing.
• Skin rash.
• Bad taste in the mouth.
• Problems identifying smells.
• Feeling irritable.
• Runny nose.
• Throat irritation.
• Allergy (hypersensitivity)
### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UNKNOWN</strong></td>
<td></td>
<td><img src="https://raw.githubusercontent.com/googlelys_SECONDARY_BRANCH/master/REPO_NAME/ABC.png" alt="✓" /></td>
</tr>
<tr>
<td>Allergic-like reaction: eye redness, itching or discomfort; increased tearing; foreign body sensation; swelling of the eye or eyelid</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

#### 3 ways to report:
- Online at [MedEffect](#);  
- By calling 1-866-234-2345 (toll-free);  
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or  
  - Mail to: Canada Vigilance Program  
    Health Canada, Postal Locator 1908C  
    Ottawa, ON  
    K1A 0K9  
    Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](#).

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### Storage:

Store between 2°C and 30°C. Do not freeze. Protect from light.

Keep out of reach and sight of children.

### If you want more information about IOPIDINE 0.5%:
- Talk to your healthcare professional  
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](#); the manufacturer’s website [www.novartis.ca](http://www.novartis.ca), or by calling 1-800-363-8883.

This leaflet was prepared by Novartis Pharmaceuticals Canada Inc.  
Last Revised: February 8, 2018
IOPIDINE® is a registered trademark